Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.
- Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.
- Entered exclusive distribution and supply agreement with Biologix for ganaxolone in select markets in the Middle East and North Africa.
- Recognized $3.3 million in net product revenues for the three months ended March 31, 2023.
- Net product revenue consists of ZTALMY product sales, which was launched in the U.S. in the third quarter of 2022.